Key People/Management at InVitae

Sean George

Sean George

Chief Executive Officer, Director
Lee Bendekgey

Lee Bendekgey

Chief Operating Officer
Tom Brida

Tom Brida

General Counsel
Shelly Guyer

Shelly Guyer

Chief Financial Officer
Robert Nussbaum

Robert Nussbaum

Chief Medical Officer
Katherine Stueland

Katherine Stueland

Chief Commercial Officer
Show more

InVitae Office Locations

InVitae has an office in San Francisco
San Francisco, US (HQ)
1400 16th St, San Francisco
Show all (1)

InVitae Financials and Metrics

InVitae Revenue

InVitae's revenue was reported to be $216.82 m in FY, 2019
USD

Revenue (Q2, 2020)

46.2m

Gross profit (Q2, 2020)

3.2m

Gross profit margin (Q2, 2020), %

7%

Net income (Q2, 2020)

(166.4m)

EBIT (Q2, 2020)

(142.1m)

Market capitalization (12-Aug-2020)

3.9b

Closing stock price (12-Aug-2020)

29.8

Cash (30-Jun-2020)

168.2m

EV

4.1b
InVitae's current market capitalization is $3.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2019

Revenue

8.4m25.0m68.2m216.8m

Revenue growth, %

199%

Cost of goods sold

16.5m27.9m118.1m

Gross profit

(8.1m)(2.8m)98.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.2m1.8m2.2m4.0m5.6m6.3m10.3m14.3m18.1m27.7m37.3m37.4m40.6m53.5m56.5m64.2m46.2m

Cost of goods sold

3.2m3.9m4.0m6.0m6.5m7.2m9.3m21.3m28.0m32.1m40.4m43.0m

Gross profit

(2.0m)(2.1m)(1.8m)(2.0m)(895.0k)(966.0k)1.0m19.3m25.5m24.4m23.8m3.2m

Gross profit Margin, %

(160%)(115%)(81%)(51%)(16%)(15%)10%48%48%43%37%7%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2019

Cash

73.2m66.8m12.1m151.4m

Accounts Receivable

215.0k10.4m32.5m

Prepaid Expenses

11.6m18.0m

Inventories

4.3m9.2m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2019

Net Income

(89.8m)(100.3m)(123.4m)(242.0m)

Depreciation and Amortization

5.3m6.6m9.2m16.2m

Inventories

(1.7m)(2.0m)

Accounts Payable

508.0k(111.0k)(535.0k)1.6m
USDQ1, 2015

Financial Leverage

1.1 x
Show all financial metrics

InVitae Acquisitions / Subsidiaries

Company NameDateDeal Size
DiploidMarch 10, 2020$95 m
Singular BioJune 20, 2019$55 m

InVitae Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

InVitae Online and Social Media Presence

Embed Graph

InVitae News and Updates

Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020

SAN FRANCISCO, July 21, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m....

Invitae Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Invitae Corporation Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

NEW YORK, June 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Invitae Corporation (NYSE: NVTA) and ArcherDX is fair to Invitae shareholders. On behalf of Invitae shareholders, Halper Sadeh LLP may seek increased...

Thinking about trading options or stock in InVitae Corp, Penn National Gaming, Ford Motor Company, Bank of America, or Advanced Micro Devices?

NEW YORK, June 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVTA, PENN, F, BAC, and AMD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about buying stock in Microvision, InVitae Corp, Alpine Immune Sciences, Anavex Life Sciences, or Ford Motor?

NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, NVTA, ALPN, AVXL, and F. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Invitae to Present at the William Blair 40th Annual Growth Stock Conference

SAN FRANCISCO, May 28, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m....

Invitae launches enhanced capabilities to support telemedicine

SAN FRANCISCO, April 7, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via telemedicine for women and couples early in...
Show more

InVitae Blogs

The genetics of pancreatic cancer

When Alex Trebek was diagnosed with pancreatic cancer earlier this year, it put a spotlight on a condition that hasn’t received enough coverage: pancreatic cancer. With 56,000 adults diagnosed in the US every year, pancreatic cancer has quietly become the fourth leading cause of cancer death in men …

Now a UnitedHealthcare Preferred Lab Network Provider

Invitae is pleased to announce that we’ve been named a Preferred Lab Network Provider with UnitedHealthcare. This designation is a reflection of our ongoing commitment to making high-quality genetic testing both affordable and accessible. From UnitedHealthcare: UnitedHealthcare is working to make it…

How much do you know about genetic testing?

It’s National DNA Day, a day when students, teachers, and the public can learn more about genetics and genomics. The day commemorates the discovery of DNA’s double helix in 1953 and the completion of the Human Genome Project in 2003. To celebrate DNA Day and spread awareness of how our genes and gen…

Genetics Insider: March 2019

Literature review  New guidelines for breast surgeonsThe American Society of Breast Surgeons (ASBrS) has expanded its genetic testing guidelines. The new recommendations include: • Genetic testing should be made available to all patients with breast cancer. • Patients who had genetic testing previou…

Largest study to date on prostate cancer patients finds 17% have disease-causing variant

By Piper Nicolosi, Ph.D. In collaboration with Tulane University School of Medicine and published in JAMA Oncology,1 Invitae’s team of scientists, medical geneticists, clinical oncologists, and genetic counselors examined 3,607 men with a personal history of prostate cancer and found that approximat…

Updates to the Invitae Carrier Screen

Invitae is pleased to announce that we’ve made a number of updates and enhancements to our Invitae Carrier Screen to help better serve you and your patients. Improved panel customization We recognize that each of your patients has unique needs, which is why our carrier screen is now fully customizab…
Show more

InVitae Frequently Asked Questions

  • When was InVitae founded?

    InVitae was founded in 2010.

  • Who are InVitae key executives?

    InVitae's key executives are Sean George, Lee Bendekgey and Tom Brida.

  • How many employees does InVitae have?

    InVitae has 1,300 employees.

  • What is InVitae revenue?

    Latest InVitae annual revenue is $216.8 m.

  • What is InVitae revenue per employee?

    Latest InVitae revenue per employee is $166.8 k.

  • Who are InVitae competitors?

    Competitors of InVitae include Progenity, Center for Human Genetics and Laboratory Diagnostics and Genotyping.

  • Where is InVitae headquarters?

    InVitae headquarters is located at 1400 16th St, San Francisco, San Francisco.

  • Where are InVitae offices?

    InVitae has an office in San Francisco.

  • How many offices does InVitae have?

    InVitae has 1 office.